학술논문
British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab
Document Type
article
Author
Rebecca Dobson; Arjun K Ghosh; Bonnie Ky; Tom Marwick; Martin Stout; Allan Harkness; Rick Steeds; Shaun Robinson; David Oxborough; David Adlam; Susannah Stanway; Bushra Rana; Thomas Ingram; Liam Ring; Stuart Rosen; Chris Plummer; Charlotte Manisty; Mark Harbinson; Vishal Sharma; Keith Pearce; Alexander R Lyon; Daniel X Augustine
Source
Echo Research and Practice, Vol 8, Iss 1, Pp G1-G18 (2021)
Subject
Language
English
ISSN
2055-0464
Abstract
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.